Insider · CIK 0001907908
Alan B. Bergman
Files at AIDX (20/20 Biolabs, Inc.). First filing -, latest -.
In brief
Alan B. Bergman files SEC Form 4 as CFO at AIDX (20/20 Biolabs, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Alan B. Bergman has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 1 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Apr 2, 2026 | AIDX 20/20 Biolabs, Inc. | AGrant or award Stock Optionderivative | +100,000 | $0.00 | $0 | 100,000 | Apr 6, 2026 |
Questions about Alan B. Bergman
Answered from the filings on this page, as of the latest one.
Is Alan B. Bergman buying or selling?
Alan B. Bergman has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Alan B. Bergman's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Alan B. Bergman has 0.
Where does Alan B. Bergman file Form 4?
Alan B. Bergman has filed Form 4 at AIDX (20/20 Biolabs, Inc.) as Chief Financial Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.